Previous 10 | Next 10 |
Blueprint Medicines Reports Second Quarter 2022 Results PR Newswire -- Achieved $36.5 million in total revenues, including $28.5 million in AYVAKIT® (avapritinib) net product revenues representing 20 percent AYVAKIT revenue growth from Q1 2022 -- -- ...
Blueprint Medicines ( NASDAQ: BPMC ) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open. The consensus EPS Estimate is -$2.26 (-21.5% Y/Y) and the consensus Revenue Estimate is $37.61M (+37.8% Y/Y). Over the last 1 year, BPMC ...
Blueprint Medicines to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022 PR Newswire CAMBRIDGE, Mass. , July 26, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference ...
Raymond James updated its list of analyst favorite stocks with a swap in the restaurant subsector. Analysts can only have one favorite idea among the stocks they cover rated Strong Buy or Outperform. Ruth's Hospitality Group ( NASDAQ: RUTH ) makes it onto the Analysts Cu...
Qiming Venture Partners closed two new China healthcare and technology funds with $3.2 billion in fresh capital, both of them at their hard cap limits. Suzhou CStone Pharma announced that Gavreto® (pralsetinib) was approved in Hong Kong to treat adult patients with RET fusion-pos...
Blueprint Medicines Publishes Inaugural Corporate Responsibility Report PR Newswire -- Report highlights efforts to deliver sustainable value to patients and communities, foster a diverse and empowered workforce, and operate with exceptional integrity -- CAMB...
Blueprint Medicines ( NASDAQ: BPMC ) said it signed strategic financing collaborations with Sixth Street and Royalty Pharma ( NASDAQ: RPRX ) for up to $1.25B. Blueprint is selling royalty rights on lung cancer drug Gavreto — marketed by Roche ȁ...
Attractive, precision oncology therapy with long patent duration added to portfolio Blueprint Medicines to receive $175 million upfront and $165 million in potential milestone payments NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today an...
Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma PR Newswire Strengthens balance sheet with significant non-dilutive, low-cost capital Expands ability to bring the promise of pr...
The precision therapy company Blueprint Medicines (NASDAQ:BPMC) is trading lower in the morning hours Monday after Wells Fargo launched its coverage with an Underweight recommendation citing, among other things, a “sell the news” data readout this year. Blueprint (BPMC) plans to...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...
2024-07-10 04:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...